Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 02/29/24
Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024GlobeNewsWire • 02/22/24
Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.The Motley Fool • 02/19/24
Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian PlaySeeking Alpha • 02/08/24
Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approvedGlobeNewsWire • 01/16/24
Therapy's New Frontier: 3 Psychedelic Stocks for the Mental Health RevolutionInvestorPlace • 01/09/24
Why one backer of MDMA therapy sees ‘exponential' growth following FDA approval this yearMarket Watch • 01/03/24
Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorderGlobeNewsWire • 12/19/23
Study results of psilocybin treatment in bipolar II depression published in JAMA PsychiatryGlobeNewsWire • 12/06/23
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research centerGlobeNewsWire • 11/15/23
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 11/02/23
COMPASS Pathways plc to Announce Third Quarter 2023 Financial Results on November 2, 2023GlobeNewsWire • 10/24/23